CTOs on the Move

Eledon

www.eledon.com

 
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease. Our lead program, AT-1501, is a potential best-in-class humanized IgG1 anti-CD40L antibody with high affinity for CD40L, a well-validated biological target with broad therapeutic potential. The CD40/CD40L pathway plays a central role in generating pro-inflammatory responses in autoimmune disease, allograft transplant rejection, and neuroinflammation.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.eledon.com
  • 19900 MacArthur Boulevard Suite 550
    Irvine, CA USA 92612
  • Phone: 949.238.8090

Executives

Name Title Contact Details

Similar Companies

Ocuphire Pharma

We are a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire`s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications.

Canyon Pharmaceuticals

Canyon Pharmaceuticals is a Hunt Valley, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

New Freedom

New Freedoms 90-day reentry program inspires personal growth and accountability while treating substance abuse and other behavioral health needs.

Fifty 50 Pharmacy

Fifty 50 Pharmacy is a Carrollton, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cyteir

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir`s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors.